During the preclinical stage, the focus of forecasting is not necessarily on the product itself, but on the broader opportunity within the disease area. At this point, there is limited information ...

Following in the footsteps of the other review programs at the US Food and Drug Administration's (FDA) Office of Pharmaceutical Science, the Office of Biotechnology Products (OBP) is currently in ...

Dissolution testing in drug development evaluates supplement bioavailability and stability, crucial for maintaining quality ...